[ad_1]
FLAGSTAFF, Arizona and LUXEMBOURG CITY, Luxembourg – March 18, 2019 – The Translational Genomics Research Institute (TGen), a subsidiary of City of Hope, has taken an important step towards the eradication of tuberculosis in collaboration with an international biomedical company, Advanced Biological Laboratories (ABL), to commercialize and distribute the patented tuberculosis test technology based on next generation TGen sequencing.
For now, the test – called DeepChek®-TB – is available for research only. ABL is working on distributing a compact, portable and affordable diagnostic model that doctors around the world could use to help determine the most appropriate treatment for each patient with TB.
Current tests can take between 6 and 9 weeks. The DeepChek®-TB test can be completed in just 2-3 days and can identify drug-resistant TB among mixed infections.
Thanks to modern medicine, tuberculosis in the United States continues to pose a relatively minor threat. Globally, however, nearly one-quarter of the world's population is infected with this communicable, lung-damaging disease that kills more than 4,300 people a day, or almost three people a minute, around the world.
"Significantly, our TB dosing technology has the potential to provide physicians – even those living in relatively rural areas – with a fast and cost-effective way to accurately determine the exact drugs that can or can not be used. for each patient, "said Dr. David Engelthaler, co-director of TGen's pathogen and microbiome division.
Tuberculosis remains a major threat to public health in developing countries and is increasing in some places as mutant versions of this infectious lung disease become resistant to current drug treatments. Identifying drug-fast and drug-resistant TB strains is the biggest challenge to eradicate this disease.
ABL, based in Luxembourg, is one of the leading manufacturers of diagnostic solutions and medical technologies. Its licensing agreement with TGen will allow ABL to distribute DeepChek®-TB through its global network of clinicians and distributors in more than 80 countries.
"We look forward to immediately making the DeepChek®-TB test available to our global network, and we expect a strong demand for this test from leading research facilities around the world," the company said. Dr. Chalom Sayada, founder and CEO of ABL.
As part of the UNITAID TB strategy of the World Health Organization (WHO), the DeepChek®-TB test could help achieve the goal of a reduction of 95 % of TB deaths and 90% of new cases by 2035.
In the United States, more than 9,000 TB cases are diagnosed each year, a reduction of over 80% from 50 years ago. However, current drug-resistant tuberculosis is a heavy burden on the health system, costing an average of more than $ 500,000 to treat each of the most resistant patients.
"This is a precision medical test, that is, designed to provide treatment-specific information to each patient," Dr. Engelthaler said. "Drug resistance occurs when the wrong antibiotics are prescribed at the wrong time.This new approach aims not only to help doctors better treat patients, but also to slow down or stop the global threat Mycobacterium tuberculosis multi-resistant."
###
About TGen, a subsidiary of City of Hope
The Translational Genomics Research Institute (TGen) is a non-profit organization based in Phoenix, Arizona, dedicated to delivering innovative research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes, and other life-threatening diseases: http: // www.
Media contact:
Steve Yozwiak
TGen Senior Scientific Editor
602-343-8704
[email protected]
About Advanced Biological Laboratories (ABL SA)
Advanced Biological Laboratories (ABL), S.A., is a diagnostic and medical software company founded in 2000 following the creation of CRP-Santé Luxembourg. ABL products offer clinicians specializing in infectious diseases, as well as virology and microbiology laboratories, optimal and effective solutions (tests and software systems for HIV, tuberculosis, HCV, HBV, HPV, HPV, HPV, …) for clinical genotyping (DeepChek®), viral load badysis (UltraGene ™) and drug resistance, including powerful fully integrated databases and badysis systems combining standard next-generation and high-throughput sequencing data. ABL took control of TherapyEdge, Inc. in 2004 and 2013 on the rights of all badets related to viral hepatitis and hepatitis B from C EVIVAR MEDICAL as well as a system electronic medical record for personalized medicine in the field of infectious diseases of GlaxoSmithKline in 2016. In July In 2018, he acquired CDL Pharma to develop ORC-related services and badytical production capacity. In March 2019, ABL signed a non-exclusive worldwide licensing agreement for the distribution of IntegraGen's patented IVD CE miRpredX ™ diagnostic test, which allows clinicians to identify patients with specific medical conditions. a metastatic colorectal cancer presenting a higher risk of response to anti-EGFR therapy. ABL offers a full line of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC® and DPM for data and patient management, monitoring and custom reporting. In 2012, some ABL products also received the CE mark for the use of in vitro diagnostics. ABL products such as ViroScore® Suite and DeepChek® are intended for research only in the United States and the data processing module is a Clbad I medical device registered by the FDA. These are currently available for search only.
Media contact:
Dr. Chalom Sayada
Advanced biological laboratories
[email protected]
+352 263896761
Warning: AAAS and EurekAlert! are not responsible for the accuracy of the news releases published on EurekAlert! contributing institutions or for the use of any information via the EurekAlert system.
Source link
